Competition from compounded medications, which offered semaglutide at significantly lower prices, likely also influenced the decision to make brand-name options more competitive
Path 2: Moderate BMI + Serious Health Condition BMI of 30 or higher PLUS one of these: Heart failure (ask your doctor if you have "preserved ejection fraction" type) High blood pressure that's hard to control (still above 140/90 despite 2+ medicines) Chronic kidney disease (stage 3a or higher your doctor can confirm) Path 3: Lower BMI + Heart/Stroke History BMI of 27 or higher PLUS one of these: Pre-diabetes Previous heart attack Previous stroke Peripheral artery disease with symptoms (leg pain when walking) Important timing: These requirements are based on when you FIRST started the GLP-1 medication not your current weight or health
That requires a responsive and resilient manufacturing ecosystem
Umpierrez G, Tofe Povedano S, Perez Manghi F, Shurzinske L, Pechtner V, et al
Recurring complaints about the same issues, billing disputes, refund denials, and product quality, suggest systemic problems rather than isolated incidents
Each comes with different costs, risks, and legal considerations
